Drug Policy - High-Value Therapies for Patients Archives - Kaiser Permanente Institute for Health Policy

Publications from PORTAL

Kaiser Permanente is proud to partner with the Program on Regulation, Therapeutics, and Law (PORTAL), out of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital/Harvard Medical School, to uncover trends in pharmaceutical evidence generation and highlight the clinical benefits…

How pharmaceutical marketing affects decisions about patient care

As we search for ways to improve the value of prescription drugs and make them more affordable, pharmaceutical marketing poses a real challenge. Pharmaceutical marketing aims to shape perceptions about a drug’s benefits and harms, and this can significantly impact…

A man handing a prescription to a pharmacists

Restoring Provider Confidence In FDA-Approved Drugs

The Kaiser Permanente Institute for Health Policy's experts Samantha Dupont, Krysten Joyce and Murray Ross join Kaiser Permanente's Senior Vice President of Government Relations, Tony Barrueta, to share their insights on the policy prescriptions needed to ensure prescribed drugs are…

Evolving nature of evidence required by FDA to approve new drugs

This brief, based on systematic reviews conducted in collaboration with the Program on Therapeutics, And Law (PORTAL), provides background on the evidence required by the Food and Drug Administration (FDA) to support drug approval. It highlights changes in the amount…

Building Racial Equity into the Drug Development System: Clinical Trials, Access, and Affordability

March 1, 2021
Drug Policy, Drug Policy - Fostering Competitive Markets, Drug Policy - High-Value Therapies for Patients, Health Equity

This webinar is the second in a two-part series that looks at racial equity in the drug development system, from investment all the way through access. This forum will focus on equity in the patent system, clinical trials, healthcare delivery, and affordability.

Building Racial Equity into the Drug Development System

December 7, 2020
Digital Health, Drug Policy, Drug Policy - High-Value Therapies for Patients, Health Equity

Kaiser Permanente’s Institute for Health Policy invites you to join a two-part virtual forum examining racial equity in the drug development system, from research all the way through to access. This first conversation on December 7 will specifically explore racial inequities in drug investment and research and identify new directions for the future.

Kaiser Permanente Institute for Health Policy

When the best prescription is deprescribing

Several years ago, an elderly patient — let’s call her Eve — came to Kaiser Permanente because she was dazed and feeling “out of it” on a regular basis. Her family chalked it up to old age and eventually contemplated…

Determining drug value: Let’s start with the evidence

Last month, I was pleased to speak at the Institute for Health Policy forum that delved into a critical topic in the drug pricing dialogue: drug value. When I arrived in Washington, D.C., I was struck by how far we’ve…

It’s time to change drug companies’ harmful marketing practices

Over the course of the past year, we’ve seen renewed interest from federal policymakers in curbing pharmaceutical industry marketing practices that increase drug spending for patients, taxpayers, and the health care system as a whole. This week, the U.S. Department…

High Cost of Prescription Drugs: Concept prescription bottles with gavel

A deeper dive: Recommendations for strengthening the FDA’s REMS program to protect patients

Last month, Institute for Health Policy Director Murray Ross shared a post on Kaiser Permanente’s response to U.S. Department of Health and Human Services’ request for comments on its “Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.”